# CoJourney

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cojourney

- Industry: Pharmaceuticals
- Headquarters: Philadelphia, US
- Website: www.cojourney.com/en/
- Total disclosed funding: $30M
- Latest round: Series A (Jun 26, 2023)
- Investors on record: 6

## About

Based in Pennsylvania, US, and founded in 2021, CoJourney Inc. operates as a pharmaceutical company that is a manufacturer of cell and gene therapies through platform technologies such as plasmids, mRNA, etc. In July 2023, CoJourney Inc. raised USD 30 million in series A funding from Legend Holdings, Legend Star, Lake Bleu Capital, GL Ventures, etc. 

CoJourney Inc. is a company that provides a CDMO (Contract Development and Manufacturing Organisation) platform for gene therapy that is designed for plasmids, viral vectors, and mRNA. The company's platform includes the creation, analysis, and testing of genetic materials. As a result, gene therapy developers are able to obtain access to personalized services such as process development, cGMP manufacturing, analytical method development, and product release testing.

The company plans to use the June 2023 funding to expand its market reach in the US.

## Funding rounds

- Series A, Jun 26, 2023, $30M — Legend Holdings, Kaitai Capital, Legend Star, K2VC, GL Ventures, Lake Bleu Capital

## Investors

- Legend Holdings — Series A
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series A
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series A